SMARCA4 and cancer: Some reports have implied that because BRG1 is mutated in cell lines, it must also be mutated to the same degree in primary tumors (95), and BRG1 has been shown to be silenced by mutations in >65–70% of human cancer cell lines in a number of studies (94–96).